Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash from Operations (2016 - 2025)

Standard Biotools (LAB) has disclosed Cash from Operations for 16 consecutive years, with 22202000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 20.33% to 22202000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 87212000.0, a 39.21% increase, with the full-year FY2024 number at 143454000.0, down 231.4% from a year prior.
  • Cash from Operations was 22202000.0 for Q3 2025 at Standard Biotools, down from 20668000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 7002000.0 in Q4 2021 to a low of 62476000.0 in Q1 2024.
  • A 5-year average of 20701315.79 and a median of 15590000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: soared 68.89% in 2023, then crashed 636.31% in 2024.
  • Standard Biotools' Cash from Operations stood at 7002000.0 in 2021, then plummeted by 173.94% to 19181000.0 in 2022, then grew by 26.69% to 14061000.0 in 2023, then grew by 0.01% to 14059000.0 in 2024, then plummeted by 57.92% to 22202000.0 in 2025.
  • Per Business Quant, the three most recent readings for LAB's Cash from Operations are 22202000.0 (Q3 2025), 20668000.0 (Q2 2025), and 30283000.0 (Q1 2025).